ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in...
MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. The company’s lead compound Bulevirtide (Myrcludex) is currently progressing into a Phase 3 studyies in the indication of chronic HDV infection.
Bulevirtide (Mycludex) is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the NTCP receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Bulevirtide has received the Orphan Drug Designation for treatment of HDV infection from the European Medicines Agency (EMA) and from the U.S. Food & Drug Administration (FDA). In addition, the EMA has granted PRIority MEdicines (PRIME) scheme eligibility. In parallel the FDA has granted Breakthrough Therapy designation and the British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation.
As an inhibitor of bile acid transporter NTCP, bulevirtide (Mycludex) also opens up new possibilities for the treatment of a variety of inflammatory and metabolic diseases.